Colletotrichum, plague and brucellosis triple RPA detection kit, primer probe composition and application
Through LFD-RPA technology and specific primer probe compositions, combined with lateral flow test strips, the on-site rapid and specific problems of anthrax, plague and brucellosis detection in the prior art are solved, and the rapid and accurate field in the field is achieved. Testing, suitable for grassroots testing.
Patent Information
- Application Number
- CN202411091115.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-19
AI Technical Summary
The existing detection methods for anthrax, plague and brucellosis require precision instruments and professional technical personnel, and it is difficult to conduct rapid and accurate detection in the field, especially the specificity and sensitivity of the three pathogens simultaneously are difficult to achieve.
Using kits and primer probe compositions based on LFD-RPA technology, including specific primers and probe sequences, combined with lateral flow test strips, to achieve rapid, sensitive and specific detection of anthrax, plague and Brucella, suitable for On-site inspection at the grassroots level.
It realizes rapid and accurate detection of anthrax, plague and Brucella without large-scale instruments and equipment and professional technicians, with good specificity and sensitivity, suitable for basic-level on-site testing, suitable for environmental samples, clinical samples and Simulate samples.
Smart Images

Figure CN118979116A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a triple RPA detection kit for anthrax, plague and brucellosis, a primer-probe combination and an application thereof. Background Art
[0002] Bacillus anthracis ( Bacillus anthracis 、Yersinia pestis( Yersinia pestis ) and Brucella ( Brucella ) can cause severe anthrax, plague and brucellosis in humans and animals, posing a serious threat to public health. Herbivores usually become ill when they ingest anthrax spores in the soil while grazing, and usually die quickly. People are usually infected with anthrax by ingesting or coming into contact with these dead animals; plague is spread through the bites of rat fleas, and is fast in transmission, highly contagious, and has a high mortality rate; brucellosis is usually caused by direct contact with infected animals, eating or drinking contaminated animal products, or inhaling pathogens in the air. Early detection and diagnosis of the above three pathogens are extremely important for the spread and control of the disease.
[0003] Molecular biological detection methods based on polymerase chain reaction (PCR) and real-time fluorescence quantitative PCR (qPCR) have been widely used in the detection of pathogens. Although these methods can accurately detect pathogens, they often take a long time and rely on precise instruments (such as qPCR instruments) and professional biotechnical personnel, making it basically impossible to achieve field detection. Recombinase polymerase amplification (RPA) is a new type of nucleic acid constant temperature amplification technology with an optimal temperature of 37-42°C. It can achieve rapid detection of the target to be tested within 10-30 minutes. It has the advantages of high sensitivity, strong specificity, low dependence on instruments, and the integration of multiple detection modes. It is particularly suitable for grassroots and on-site instant detection. Lateral flow dipsticks (LFDs) technology is a classic bedside detection method based on antigen-antibody immune response, which has the advantages of rapidity, simplicity, and low cost. Combining RPA and LFD can realize visual detection of amplification products without the need for complex instruments and equipment. It is suitable for rapid on-site detection and has extremely broad application prospects.
[0004] Based on LFD-RPA technology, how to simultaneously achieve specific and sensitive detection of three pathogens, namely, Bacillus anthracis, Yersinia pestis and Brucella, is one of the hot topics of concern to technicians in this field. Summary of the invention
[0005] The present invention provides a kit, a primer-probe combination and application for detecting anthrax bacillus, pestis bacillus and brucella based on LFD-RPA.
[0006] The present invention also provides a kit, a primer-probe combination and an application thereof for detecting anthrax bacillus, pestis bacillus and brucella based on RPA.
[0007] In a first aspect, the present invention provides a kit for detecting anthrax bacillus, pestis bacillus and brucella, comprising a composition for detecting anthrax bacillus, a composition for detecting pestis bacillus, a composition for detecting brucella and a lateral flow test paper; The composition for detecting anthrax bacillus comprises primer lefRPA-F, primer lefRPA-R-1 and probe lefRPA-Probe-1; the composition for detecting pestis bacillus comprises primer YP01-3F, primer YP01-3R-1 and probe YP01-3Prboe-1; the composition for detecting Brucella comprises primer bscp31RPA-F, primer bscp31RPA-R-1 and probe bscp31RPA-Probe-1; The general structural formula of the probe lefRPA-Probe-1, the probe YP01-3Prboe-1 and the probe bscp31RPA-Probe-1 is shown in Formula 1: 5'-X-(n)aH-(n)bY-3' Formula 1; In Formula 1, X is the second labeling group, (n)a is the first single-stranded DNA molecule, H is a tetrahydrofuran residue, (n)b is the second single-stranded DNA molecule, and Y is a blocking group; The primer lefRPA-F is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:1, and the primer lefRPA-R-1 is a single-stranded DNA with a nucleotide sequence modified by a first labeling group as shown in SEQ ID NO:2; in the probe lefRPA-Probe-1, (n)a is a single-stranded DNA molecule with a nucleotide sequence as shown in SEQ ID NO:3, and (n)b is a single-stranded DNA molecule with a nucleotide sequence as shown in SEQ ID NO:4; The primer YP01-3F is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:5, and the primer YP01-3R-1 is a single-stranded DNA with a nucleotide sequence modified with a first labeling group as shown in SEQ ID NO:6; in the probe YP01-3Prboe-1, (n)a is a single-stranded DNA molecule with a nucleotide sequence as shown in SEQ ID NO:7, and (n)b is a single-stranded DNA molecule with a nucleotide sequence as shown in SEQ ID NO:8; The primer bscp31RPA-F is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:9, the primer bscp31RPA-R-1 is a single-stranded DNA with a nucleotide sequence modified by a first labeling group as shown in SEQ ID NO:10, and in the probe bscp31RPA-Probe-1, (n)a is a single-stranded DNA molecule with a nucleotide sequence as shown in SEQ ID NO:11, and (n)b is a single-stranded DNA molecule with a nucleotide sequence as shown in SEQ ID NO:12.
[0008] In the kit as described above, the primer lefRPA-F is a forward primer, the primer lefRPA-R-1 is a reverse primer, and the first nucleotide at the 5' end of the primer lefRPA-R-1 is labeled with a first labeling group.
[0009] In the kit as described above, primer YP01-3F is a forward primer, primer YP01-3R-1 is a reverse primer, and the first nucleotide at the 5' end of primer YP01-3R-1 is labeled with a first labeling group.
[0010] In the kit as described above, the primer bscp31RPA-F is a forward primer, the primer bscp31RPA-R-1 is a reverse primer, and the first nucleotide at the 5' end of the primer bscp31RPA-R-1 is labeled with a first labeling group.
[0011] Furthermore, the first labeling group is a small molecule compound that can be recognized by a monoclonal antibody, such as biotin or a fluorescent group. Furthermore, the first nucleotide at the 5' end of primers lefRPA-R-1, YP01-3R-1, and bscp31RPA-R-1 is labeled with biotin.
[0012] In the above-mentioned kit, the general structural formula of the above-mentioned probe lefRPA-Probe-1, probe YP01-3Prboe-1 and probe bscp31RPA-Probe-1 is shown in Formula 1: 5'-X-(n)aH-(n)bY-3' Formula 1; In Formula 1, X is the second labeling group, (n)a is the first single-stranded DNA molecule, H is a tetrahydrofuran residue, (n)b is the second single-stranded DNA molecule, and Y is a blocking group.
[0013] Furthermore, the second labeling groups X labeled at the 5' end of the probe lefRPA-Probe-1, probe YP01-3Prboe-1, and probe bscp31RPA-Probe-1 are different so as to bind to different antibodies coated on the detection area of the lateral flow test paper. The second labeling groups labeled at the 5' end of the probe lefRPA-Probe-1, probe YP01-3Prboe-1, and probe bscp31RPA-Probe-1 are independently selected fluorescent groups, digoxin, and other small molecule compounds that can be recognized by monoclonal antibodies.
[0014] Furthermore, the fluorescent group is selected from one or more of FITC, TAMRA, FAM, HEX, CY3, CY5, ROX, and Texas Red.
[0015] Furthermore, the 5' end of the probe lefRPA-Probe-1 is labeled with a fluorescent group FITC; the 5' end of the probe YP01-3Prboe-1 is labeled with digoxigenin DIG; and the 5' end of the probe bscp31RPA-Probe-1 is labeled with a fluorescent group TAMRA.
[0016] Furthermore, the blocking group is a group with the purpose of blocking nucleic acid extension. Furthermore, the blocking group is independently selected from one or more of C3 Spacer, C6 Spacer, and C9 Spacer. Furthermore, the 3' end of the probe lefRPA-Probe-1, the probe YP01-3Prboe-1, and the probe bscp31RPA-Probe-1 are all labeled with C3Spacer.
[0017] In the kit as described above, the concentrations of the primer lefRPA-F, primer lefRPA-R-1, probe lefRPA-Probe-1, primer YP01-3F, primer YP01-3R-1, probe YP01-3Prboe-1, primer bscp31RPA-F, primer bscp31RPA-R-1, and probe bscp31RPA-Probe-1 are 10 μmol / L-100 μmol / L.
[0018] In the above-mentioned test kit, the lateral flow test paper includes a sample pad, a conjugate pad, a detection area and a water absorbent pad in sequence along the liquid flow direction, wherein the conjugate pad is attached with a colloidal gold marker, and the colloidal gold marker is a combination of colloidal gold and a substance that specifically binds to the first marker group. Further, when the first marker group is biotin, the substance that specifically binds to the first marker group is a monoclonal antibody against biotin. The detection area includes an anthrax Bacillus detection line, a pestis Bacillus detection line, a brucella detection line and a quality control line, and the anthrax Bacillus detection line, the pestis Bacillus detection line and the brucella detection line are respectively coated with antibodies against the second labeling group; specifically, when the second labeling group labeled on the probe lefRPA-Probe-1 used to detect anthrax Bacillus is FITC, the anthrax Bacillus detection line is coated with an anti-FITC antibody, named anti-FITC; when the second labeling group labeled on the probe YP01-3Prboe-1 used to detect pestis Bacillus is DIG, the anthrax Bacillus detection line is coated with an anti-DIG antibody, named anti-DIG; when the second labeling group labeled on the probe bscp31RPA-Probe-1 used to detect Brucella is TARMA, the Brucella detection line is coated with an anti-TARMA antibody, named anti-TARMA.
[0019] Furthermore, the lateral flow test paper may be in a strip shape, ie, a lateral flow test paper strip.
[0020] The kit as described above also includes enzymes required for the RPA reaction, including recombinase, single-stranded DNA binding protein and strand displacement DNA polymerase.
[0021] In a second aspect, the present invention provides a kit for detecting anthrax bacillus, pestis bacillus and brucella, comprising a composition for detecting anthrax bacillus, a composition for detecting pestis bacillus and a composition for detecting brucella; The composition for detecting anthrax bacillus comprises primer lefRPA-F, primer lefRPA-R and probe lefRPA-Probe; the composition for detecting pestis bacillus comprises primer YP01-3F, primer YP01-3R and probe YP01-3Prboe; the composition for detecting Brucella comprises primer bscp31RPA-F, primer bscp31RPA-R and probe bscp31RPA-Probe; The structure of the probe is shown in Formula 2: 5'-(n)cH-(n)dY-3' Formula 2; In Formula 2, (n)c is a first single-stranded DNA molecule modified with a fluorescent group, H is a tetrahydrofuran residue, (n)d is a second single-stranded DNA molecule modified with a quenching group, and Y is a blocking group; The primer lefRPA-F is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO: 1, the primer lefRPA-R is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO: 2, and in the probe lefRPA-Probe, (n)c is a single-stranded DNA molecule with a nucleotide sequence modified with a fluorescent group as shown in SEQ ID NO: 3, and (n)d is a single-stranded DNA molecule with a nucleotide sequence modified with a quenching group as shown in SEQ ID NO: 4; The primer YP01-3F is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:5, the primer YP01-3R is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:6, and in the probe YP01-3Prboe, (n)c is a single-stranded DNA molecule with a nucleotide sequence modified with a fluorescent group as shown in SEQ ID NO:7, and (n)d is a single-stranded DNA molecule with a nucleotide sequence modified with a quenching group as shown in SEQ ID NO:8; The primer bscp31RPA-F is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:9, the primer bscp31RPA-R is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:10, and in the probe bscp31RPA-Probe, (n)c is a single-stranded DNA molecule with a nucleotide sequence modified with a fluorescent group as shown in SEQ ID NO:11, and (n)d is a single-stranded DNA molecule with a nucleotide sequence modified with a quenching group as shown in SEQ ID NO:12.
[0022] In the kit as described above, the fluorescent group is independently selected from at least one of FAM, VIC, HEX, TRT, CY3, CY5, ROX, JOE, FITC, TET, NED, TAMRA, LC RED460, LC RED705, Quasar705, and Texas Red; the quenching group is independently selected from one of BHQ1, BHQ2, BHQ3, MGB, and Eclipse.
[0023] In the kit as described above, the fluorescent group is modified on the first nucleotide or the second nucleotide at the 3' end of the first single-stranded DNA molecule, the quenching group is modified on the first nucleotide or the second nucleotide at the 5' end of the second single-stranded DNA molecule, and the first single-stranded DNA molecule and the second single-stranded DNA molecule are connected via a tetrahydrofuran residue.
[0024] Furthermore, in the probe lefRPA-Probe, the second nucleotide at the 3' end of the single-stranded DNA molecule whose nucleotide sequence is shown in SEQ ID NO:3 is modified with a fluorescent group FAM, the second nucleotide at the 5' end of the single-stranded DNA molecule whose nucleotide sequence is shown in SEQ ID NO:4 is modified with a quenching group BHQ1, and the first nucleotide at the 3' end is modified with a blocking group C3-spacer; and the first nucleotide at the 3' end of the single-stranded DNA shown in SEQ ID NO:3 modified with the fluorescent group FAM and the first nucleotide at the 5' end of the single-stranded DNA shown in SEQ ID NO:4 modified with the quenching group BHQ1 are connected by a tetrahydrofuran residue.
[0025] Furthermore, in the probe YP01-3Prboe, the second nucleotide at the 3' end of the single-stranded DNA molecule whose nucleotide sequence is shown in SEQ ID NO:7 is modified with a fluorescent group HEX, the second nucleotide at the 5' end of the single-stranded DNA molecule whose nucleotide sequence is shown in SEQ ID NO:8 is modified with a quenching group BHQ1, and the first nucleotide at the 3' end is modified with a blocking group C3-spacer; and the first nucleotide at the 3' end of the single-stranded DNA shown in SEQ ID NO:7 modified with the fluorescent group HEX and the first nucleotide at the 5' end of the single-stranded DNA shown in SEQ ID NO:8 modified with the quenching group BHQ1 are connected by a tetrahydrofuran residue.
[0026] Furthermore, in the probe bscp31RPA-Probe, the first nucleotide at the 3' end of the single-stranded DNA molecule whose nucleotide sequence is shown in SEQ ID NO:11 is modified with a fluorescent group Texas Red, the first nucleotide at the 5' end of the single-stranded DNA molecule whose nucleotide sequence is shown in SEQ ID NO:12 is modified with a quenching group BHQ2, and the first nucleotide at the 3' end is modified with a blocking group C3-spacer; and the first nucleotide at the 3' end of the single-stranded DNA shown in SEQ ID NO:11 modified with the fluorescent group Texas Red and the first nucleotide at the 5' end of the single-stranded DNA shown in SEQ ID NO:12 modified with the quenching group BHQ2 are connected by a tetrahydrofuran residue.
[0027] In a third aspect, the present invention provides a composition, comprising at least one of the composition for detecting anthrax Bacillus, the composition for detecting pestis Bacillus, and the composition for detecting Brucella in the kit provided in the first aspect of the present invention.
[0028] In a fourth aspect, the present invention provides a composition, comprising at least one of the composition for detecting anthrax Bacillus, the composition for detecting pestis Bacillus, and the composition for detecting Brucella in the kit provided in the second aspect of the present invention.
[0029] In a fifth aspect, the present invention provides the use of any of the above-mentioned kits and / or compositions in any of the following aspects: A1) Detection or auxiliary detection of pathogens; A2) Preparation of products for pathogen detection or auxiliary detection; The pathogenic bacteria is at least one of anthrax bacillus, pestis bacillus and brucella.
[0030] It is understandable that when only one or two of anthrax Bacillus, pestis and Brucella are detected, the kit provided in the first aspect of the present invention can be used, or a primer-probe combination for detecting one or two of anthrax Bacillus, pestis and Brucella can be used for detection, and the present invention does not impose further limitations on this.
[0031] In a sixth aspect, the present invention provides a method for detecting pathogenic bacteria, comprising: B1) Extract genomic DNA of the sample to be tested; B2) using the genomic DNA as a template, performing LFD-RPA detection using the composition provided in the third aspect of the present invention or the kit provided in the first aspect of the present invention; determining whether the sample to be tested contains the pathogen according to the bands in the lateral flow test paper; The pathogenic bacteria is at least one of anthrax bacillus, pestis bacillus and brucella.
[0032] The method as described above determines whether the sample to be tested contains at least one of anthrax bacillus, plague bacillus and brucella according to the strips in the lateral flow test paper, and specifically includes: the detection area of the lateral flow test paper (abbreviated as LFD test paper) includes an anthrax bacillus detection line, a plague bacillus detection line, a Brucella detection line and a quality control line; if a red strip appears on the quality control line of the LFD test paper and at least one red strip appears on the three detection lines, the result is positive, indicating that the sample to be tested contains at least one pathogen of anthrax bacillus, plague bacillus and Brucella; if only one red strip appears on the quality control line of the LFD test paper, the result is negative, indicating that the sample to be tested does not contain any of anthrax bacillus, plague bacillus and Brucella; if no red strip appears on the LFD test paper, it indicates that the test result is invalid.
[0033] As described above, the total volume of the reaction system for LFD-RPA detection in step B2) is 50 μL: including 29.5 μL buffer, 1.1 μL primer lefRPA-F, 1.1 μL primer lefRPA-R-1, 1.1 μL primer YP01-3F, 1.1 μL primer YP01-3R-1, 1.1 μL primer bscp31RPA-F, 1.1 μL primer bscp31RPA-R-1, 0.1 μL probe lefRPA-Probe-1, 0.1 μL probe YP01-3RPA-Probe-1, 0.4 μL probe bscp31RPA-Probe-1 (the concentrations of the above six primers and three probes are all 10 μmol / L), 7.8 μL DEPC water, 3 μL genomic DNA of the sample to be tested, and 2.5 μL 280 mmol / L MgOAc solution.
[0034] According to the method described above, the above reaction system is added to the RPA freeze-dried enzyme powder to perform the RPA amplification reaction. After the reaction is completed, the amplification product is dripped onto the LFD test paper for detection. Furthermore, the temperature of the RPA amplification reaction is 39°C, the reaction time is 10 minutes, and after the amplification product is dripped onto the LFD test paper, it is placed at room temperature for 10 minutes and then observed.
[0035] In a seventh aspect, the present invention provides a method for detecting pathogenic bacteria, comprising: C1) Extract genomic DNA of the sample to be tested; C2) using the genomic DNA as a template, performing RPA detection using the composition provided in the fourth aspect of the present invention or the kit provided in the second aspect of the present invention; determining whether the sample to be tested contains the pathogen according to the intensity of the fluorescent signal; The pathogenic bacteria is at least one of anthrax bacillus, pestis bacillus and brucella.
[0036] The detection methods provided in the sixth and seventh aspects of the present invention are methods for non-disease diagnosis purposes and are used to detect whether pathogens exist in a sample.
[0037] The samples to be tested provided in the sixth and seventh aspects of the present invention may be environmental samples, clinical samples, articles, etc.
[0038] The present invention provides a kit, a primer-probe combination and a method for detecting anthrax Bacillus, pestis Bacillus and brucella based on LFD-RPA. The kit is simple, rapid, sensitive and specific, and can specifically detect any one of anthrax Bacillus, pestis Bacillus and brucella from different pathogens. It does not require large-scale instruments and equipment and professional technicians, and is suitable for completing pathogen detection in samples at the grassroots level.
[0039] The present invention provides a kit, a primer-probe combination and a method for detecting anthrax bacillus, pestis bacillus and brucella based on RPA, which has the characteristics of good specificity and high sensitivity, and can simultaneously detect anthrax bacillus, pestis bacillus and brucella in one reaction tube without cross reaction.
[0040] The present invention applies two detection kits to newly isolated strains, clinical blood samples and simulated samples. Experimental results show that the two detection kits have good effects in clinical blood specimens, isolated strains and simulated samples. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 The RPA specific detection results of the primer-probe combination for detecting anthrax Bacillus, pestis Bacillus and Brucella; wherein A is the result of single-plex RPA detection of DNA samples of seven pathogens using the primer-probe combination for detecting anthrax Bacillus, B is the result of single-plex RPA detection of DNA samples of seven pathogens using the primer-probe combination for detecting pestis Bacillus, and C is the result of single-plex RPA detection of DNA samples of seven pathogens using the primer-probe combination for detecting Brucella; Figure 2 The RPA sensitivity test results of the primer-probe combination for detecting anthrax Bacillus, pestis Bacillus and Brucella; wherein A is the sensitivity of the primer-probe combination for detecting anthrax Bacillus to different concentrations of anthrax Bacillus. lef The single-plex RPA detection results of the gene are shown in Figure 2, and B is the detection result of the primer-probe combination for detecting Yersinia pestis at different concentrations. YP01-3 The single-plex RPA detection results of the gene, C is the primer-probe combination for detecting Brucella for Brucella bscp31 Single-plex RPA test results of genes; ns means not significant, * means P ≤0.05; Figure 3 The multiple RPA detection results of the primer-probe combination for detecting anthrax Bacillus, plague Bacillus and Brucella; wherein A is the double RPA detection result of the primer-probe combination for detecting anthrax Bacillus and plague Bacillus on four pathogen combinations and two pathogens, B is the double RPA detection result of the primer-probe combination for detecting plague Bacillus and Brucella on four pathogen combinations and two pathogens, C is the double RPA detection result of the primer-probe combination for detecting anthrax Bacillus and Brucella on four pathogen combinations and two pathogens, and D is the triple RPA detection result of the primer-probe combination for detecting anthrax Bacillus, plague Bacillus and Brucella on eight pathogen combinations; Figure 4The LFD-RPA detection results of the primer-probe combination for detecting anthrax Bacillus, plague Bacillus and Brucella; wherein A is the detection result of the primer-probe combination for detecting anthrax Bacillus and plague Bacillus on pathogens, B is the detection result of the primer-probe combination for detecting Brucella and plague Bacillus on pathogens, C is the detection result of the primer-probe combination for detecting anthrax Bacillus and Brucella on pathogens, and D is the detection result of the primer-probe combination for detecting anthrax Bacillus, plague Bacillus and Brucella on pathogens; Figure 5 The present invention is a method for detecting the RPA detection results and LFD-RPA detection results of the primer probe combination for detecting Bacillus anthracis, Yersinia pestis and Brucella on clinical samples, isolates and simulated samples; wherein, A is the RPA detection result and LFD-RPA detection result of the primer probe combination for detecting Bacillus anthracis, Yersinia pestis and Brucella on clinical blood samples numbered S1-S19, B is the PCR detection result of the clinical blood samples numbered S1-S19, C is the RPA detection result and LFD-RPA detection result of the primer probe combination for detecting Bacillus anthracis, Yersinia pestis and Brucella on Bacillus anthracis Xa01, D is the PCR detection result of Bacillus anthracis Xa01, E is the RPA detection result and LFD-RPA detection result of the primer probe combination for detecting Bacillus anthracis, Yersinia pestis and Brucella on plague simulated blood genome sample, and F is the PCR detection result of plague simulated blood genome sample. DETAILED DESCRIPTION
[0042] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in conjunction with the drawings in the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments, and they should not be understood as limitations on the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. In the description of the present invention, it should be understood that the terms used are only for descriptive purposes and cannot be understood as indicating or implying relative importance.
[0043] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0044] The test strains and their sources involved in the following examples are shown in Table 1, where CICC is the China Industrial Microbiological Culture Collection Center, and its website is http: / / www.china-cicc.org / . The Yersinia pestis sample used is the Yersinia pestis EV76 genome, which is preserved in this laboratory.
[0045] Table 1 Information of tested strains
[0046] The test strains mentioned in Table 1 can all be obtained from the Military Medical Research Institute of the Academy of Military Sciences of the Chinese People's Liberation Army to repeat this experiment and cannot be used for other purposes.
[0047] Example 1, RPA detection and LFD-RPA detection 1. Preparation of bacterial genome template The test strains shown in Table 1 were cultured in solid culture media, and single colonies were picked up and cultured in liquid culture media with shaking. After culturing overnight, the bacterial solution was collected and inactivated. DNA was extracted using a bacterial genomic DNA extraction kit (TIANGEN DP302, purchased from Tiangen Biochemical Technology (Beijing) Co., Ltd.), and finally DNA was eluted with 60 μL TE buffer. The obtained genomic nucleic acid was quantified using a NanoDrop 2000 spectrophotometer to obtain a genomic template.
[0048] 2. Design and synthesis of primers and probes Based on the RPA method, the anthrax plasmid pXO1 lef gene, design forward primer lefRPA-F, reverse primer lefRPA-R and probe lefRPA-Probe. pla gene, designed forward primer YP01-3F, reverse primer YP01-3R and probe YP01-3Prboe. bscp31 gene, designed forward primer bscp31RPA-F, reverse primer bscp31RPA-R and probe bscp31RPA-Probe.
[0049] Based on the LFD-RPA method, the forward primer lefRPA-F, reverse primer lefRPA-R-1 and probe lefRPA-Probe-1 were designed for the detection of Bacillus anthracis. The forward primer YP01-3F, reverse primer YP01-3R-1 and probe YP01-3Prboe-1 were designed for the detection of Yersinia pestis. The forward primer bscp31RPA-F, reverse primer bscp31RPA-R-1 and probe bscp31RPA-Probe-1 were designed for the detection of Brucella.
[0050] The nucleotide sequences of the above primers and probes are shown in Table 2.
[0051] Table 2 Primer and probe sequences
[0052] The above primers and probes were synthesized by Jiangsu Saisuofei Biotechnology Co., Ltd. and Anhui General Biotechnology Co., Ltd., and both primers and probes were purified by HPLC.
[0053] In Table 2, 6-FAM is 6-Carboxyfluorescein; Biotin is biotin; FITC is fluorescein isothiocyanate; Dig is digoxin; TAMRA is 6-TAMRA (6-Carboxytetramethylrhodamine); HEX is 6-HEX (6-hexachloro-6-methylfluorescein); Texas Red is Texas Red, also called Sulforhodamine 101; BHQ1 and BHQ2 are quenching groups.
[0054] 3. RPA and LFD-RPA detection systems and methods 3.1. The RPA fluorescence detection method includes: extracting the DNA of the sample to be tested, using the DNA of the sample to be tested as a template, adding a total volume of 50 μL of the RPA detection system to the RPA freeze-dried enzyme powder tube (purchased from TwistDx, catalog number TABAS03KIT), performing nucleic acid amplification reaction at 39°C, and after 20 minutes of reaction, performing fluorescence signal detection on the amplified product to determine whether the sample to be tested contains at least one of anthrax bacillus, plague bacillus and Brucella. If at least one of the fluorescence signals of FAM, HEX, and Texas Red appears in the sample to be tested, it indicates that the sample to be tested contains the corresponding pathogen. If there is no fluorescence signal in the test result, it indicates that the sample to be tested does not contain any of anthrax bacillus, plague bacillus and Brucella.
[0055] Among them, the RPA detection system includes: 29.5 μL buffer, 1.1 μL primer lefRPA-F solution, 1.1 μL primer lefRPA-R solution, 1.1 μL primer YP01-3F solution, 1.1 μL primer YP01-3R solution, 1.1 μL primer bscp31RPA-F solution, 1.1 μL primer bscp31RPA-R solution, 0.3 μL probe lefRPA-Probe solution, 0.3 μL probe YP01-3Prboe solution, 0.3 μL probe bscp31RPA-Probe solution (the concentrations of the above six primer solutions and three probe solutions are all 10 μmol / L), 7.5 μL DEPC water, 3 μL nucleic acid template, and 2.5 μL 280 mmol / L MgOAc solution.
[0056] 3.2 LFD-RPA detection 3.2.1. LFD test strips were purchased from Nanjing Zhongding Biotechnology Co., Ltd. with the product number AJG10-50.
[0057] 3.2.2. The LFD-RPA detection method includes: extracting DNA from the sample to be tested, using the DNA of the sample to be tested as a template, adding RPA freeze-dried enzyme powder and LFD-RPA detection system, performing nucleic acid amplification reaction at 39°C, reacting for 10 minutes, placing the amplified product on the LFD test strip, and observing it after leaving it at room temperature for 10 minutes. Determine whether the sample to be tested contains at least one of anthrax bacillus, plague bacillus and brucella based on the LFD test strip strip. If red strips appear on both the quality control line and the corresponding test line of the LFD test strip, the result is positive, indicating that the sample to be tested contains the corresponding pathogen; if only the red strip of the quality control line appears on the LFD test strip, the result is negative, indicating that the sample to be tested does not contain any of anthrax bacillus, plague bacillus and brucella; if no red strip appears on the quality control line, the test result is invalid.
[0058] The LFD-RPA detection system includes: 29.5 μL buffer, 1.1 μL primer lefRPA-F, 1.1 μL primer lefRPA-R-1, 1.1 μL primer YP01-3F, 1.1 μL primer YP01-3R-1, 1.1 μL primer bscp31RPA-F, 1.1 μL primer bscp31RPA-R-1, 0.1 μL probe lefRPA-Probe-1, 0.1 μL probe YP01-3RPA-Probe-1, 0.4 μL probe bscp31RPA-Probe-1 (the concentrations of the above six primers and three probes are all 10 μmol / L), 7.8 μL DEPC water, 3 μL nucleic acid template, and 2.5 μL 280 mmol / L MgOAc solution.
[0059] Example 2 Detection Performance Analysis 1. Specificity analysis The genomic DNA of the test strains shown in Table 1 was used as a template, nuclease-free water was used as a blank control, and Bacillus anthracis, Yersinia pestis and Brucella were used as positive samples, respectively, to perform specificity verification analysis on the primers designed in Table 2.
[0060] The specific experimental steps are as follows: select the genomic DNA of the test strain as the template, and perform real-time fluorescence RPA reaction with the corresponding primer probe combination in Table 2. The RPA reaction system includes: 29.5μL reconstitution buffer, 2.1μL forward primer (10μmol / L), 2.1μL reverse primer (10μmol / L), 0.6μL probe (10μmol / L), 11.2μL DEPC water and 2μL nucleic acid template. Add RPA freeze-dried enzyme powder, shake evenly and centrifuge briefly, add 2.5μL 280 mmol / L MgOAc solution, shake and mix well, and centrifuge briefly. Put it into the real-time fluorescence quantitative PCR instrument, perform fluorescence signal detection according to the software operating instructions, and set up three repeated experiments. The test results are as follows: Figure 1 shown.
[0061] like Figure 1 As shown, anthrax Bacillus can be distinguished from other pathogens by primers lefRPA-F, lefRPA-R and probe lefRPA-probe; pestis can be distinguished from other pathogens by primers YP01-3RPA-F, YP01-3RPA-R and probe YP01-3RPA-Probe; Brucella can be distinguished from other pathogens by primers bscp31RPA-F, bscp31RPA-R and probe bscp31RPA-Probe. The primers and probes provided in Table 2 have good specificity and stability, and the fluorescence value of the detection reaction gradually stabilizes at 10 minutes.
[0062] 2. Sensitivity Analysis To verify the sensitivity of the RPA reaction, genomic DNA was isolated from 10 5 The number of copies / μL was gradually diluted to 10 -1 The diluted genomic DNA was used as the template and nuclease-free water was used as the blank control to perform real-time fluorescence RPA reaction. The experiment was repeated three times and the experimental data were statistically analyzed. The analysis results are shown in the figure. Figure 2 shown.
[0063] like Figure 2 As shown, the higher the template copy number, the stronger the fluorescence signal. lef , bscp31 The sensitivity of the primer-probe combination can reach 10 1 copies / μL, YP01-3 The sensitivity of the primer-probe combination can reach 10 0 copies / μL.
[0064] 3. Multiple RPA reactions The genomic DNA of two different pathogens was used as templates to perform real-time fluorescence RPA reaction with RPA primers for dual RPA detection. The dual RPA detection reaction system (50 μL) included 29.5 μL buffer, 2*1.1 μL forward primer, 2*1.1 μL reverse primer, 2*0.3 μL probe (primer and probe concentrations were both 10 μmol / L), 10 μL DEPC water, 3 μL nucleic acid template, and 2.5 μL 280 mmol / L MgOAc solution. The test results are shown in Figure 2. Figure 3 As shown in Figure AC.
[0065] The genomes of three different pathogens were used as templates and real-time fluorescence RPA reactions were performed with RPA primers for triple RPA detection. The triple RPA detection reaction system (50 μL) included 29.5 μL buffer, 1.1 μL primer lefRPA-F, 1.1 μL primer lefRPA-R, 1.1 μL primer YP01-3F, 1.1 μL primer YP01-3R, 1.1 μL primer bscp31RPA-F, 1.1 μL primer bscp31RPA-R, 0.3 μL probe lefRPA-Probe, 0.3 μL probe YP01-3Prboe, 0.3 μL probe bscp31RPA-Probe (the concentrations of the above six primers and three probes were all 10 μmol / L), 7.5 μL DEPC water, 3 μL nucleic acid template, and 2.5 μL 280 mmol / L MgOAc solution. The test results are as follows Figure 3 As shown in D.
[0066] according to Figure 3 It can be seen that both the double RPA reaction and the triple RPA reaction have good feasibility, no cross-reaction, and can detect three pathogenic bacteria simultaneously in one reaction system.
[0067] IV. LFD-RPA reaction The primer probes used to detect Bacillus anthracis include primer lefRPA-F, primer lefRPA-R-1 and primer lefRPA-Probe-1, the primer probes used to detect Yersinia pestis include primer YP01-3F, primer YP01-3R-1 and probe YP01-3Prboe-1, and the primer probes used to detect Brucella include primer bscp31RPA-F, primer bscp31RPA-R-1 and probe bscp31RPA-Probe-1. The primers and other reagents were used in the triple RPA fluorescence method. The probe ratio was lefRPA-probe-1, 0.1 μL; bscp31RPA-Probe-1, 0.4 μL; YP01-3Prboe-1, 0.1 μL, and 50 μL of the reaction system was made up with water.
[0068] Different primer-probe combinations were used to perform LFD-RPA detection on pathogens and combinations of different pathogens. The detection results were as follows: Figure 4 As shown. Figure 4 As shown, the RPA-LFDs results showed that the RPA reaction only took 10 minutes to obtain the test results with good specificity.
[0069] Example 3 RPA detection of clinical samples Genomic DNA was extracted from 19 human clinical blood samples using a blood genomic DNA extraction kit (DP304, purchased from Tiangen Biochemical Technology (Beijing) Co., Ltd.), numbered S1-S19. The S1-S19 samples were tested using the triple RPA reaction and LFD-RPA reaction in Example 2. The test results are shown in Figure 2. Figure 5 As shown in A. The bscp31-PCR method in the national standard was used as a reference to detect genomic DNA in blood samples. The primers bscp31-F and bscp31-R were used for PCR detection. The test results are shown in Figure 5 As shown in B. Figure 5 As can be seen from Figure AB, the blind test results of clinical samples detected by RPA triple fluorescence method and LFDs method are consistent with the PCR test results, indicating that the multiplex RPA detection and LFD-RPA detection provided by the present invention have good specificity.
[0070] A strain of Bacillus anthracis was isolated from the skin exudate of anthrax patients in northern China and was named Xa01. The genomic DNA samples of strain Xa01, strain A16PI2 and strain A16Q1 shown in Table 1 were tested by triple RPA reaction and LFD-RPA reaction in Example 2. The test results are shown in Figure 2. Figure 5 As shown in C. Using the national standard animal anthrax diagnostic technology (NY / T561-2015), primers pag-F and pag-R were used to perform PCR detection on genomic DNA samples of Xa01 strain, A16PI2 strain and HN001 strain, and pag and cap were used to perform PCR detection on genomic DNA samples of Xa01 strain, A16Q1 strain and HN001 strain. The test results are shown in Figure 5 As shown in D. Figure 5 As shown in Figures CD, the multiplex RPA detection and LFD-RPA detection provided by the present invention are consistent with the PCR detection results.
[0071] Since plague clinical samples are difficult to obtain, a certain amount of plague genomic DNA was added to negative blood genomic samples to simulate blood genomic samples, and the blood genomic samples were set to 10 5 Copies / μL to 10 0 copies / μL concentration gradient, with Yersinia enterocolitica 52212 ( Yersinia enterocolitica ) genomic DNA samples were used as controls. The primer-probe combination provided by the present invention was used to perform RPA and LFD-RPA tests on blood genomic samples of different concentrations. The test results were as follows: Figure 5 As shown in E. PCR detection was used as a control. The target of PCR detection of Yersinia pestis was the same as that of RPA detection. The target of pla gene and primers pla-F and pla-R in the rapid detection method of Yersinia pestis and Hantavirus in rats at border ports (SN / T 2616-2010) were used to perform PCR detection on blood genome samples of different concentrations. The test results are shown in Figure 5 As shown in F. Figure 5 As shown in Figure EF, the results of RPA detection, LFD-RPA detection and PCR detection are consistent, and can achieve the same sensitivity as PCR detection, but the time required is less than 1 / 5 of the PCR time.
[0072] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A kit for detecting anthrax bacillus, pestis bacillus and brucella, characterized in that: Comprising a composition for detecting anthrax bacillus, a composition for detecting pestis bacillus, a composition for detecting brucella and a lateral flow test paper; The composition for detecting anthrax bacillus comprises primer lefRPA-F, primer lefRPA-R-1 and probe lefRPA-Probe-1; the composition for detecting pestis bacillus comprises primer YP01-3F, primer YP01-3R-1 and probe YP01-3Prboe-1; the composition for detecting Brucella comprises primer bscp31RPA-F, primer bscp31RPA-R-1 and probe bscp31RPA-Probe-1; The general structural formula of the probe lefRPA-Probe-1, the probe YP01-3Prboe-1 and the probe bscp31RPA-Probe-1 is shown in Formula 1: 5'-X-(n)aH-(n)bY-3' Formula 1; In Formula 1, X is the second labeling group, (n)a is the first single-stranded DNA molecule, H is a tetrahydrofuran residue, (n)b is the second single-stranded DNA molecule, and Y is a blocking group; The primer lefRPA-F is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:1, and the primer lefRPA-R-1 is a single-stranded DNA with a nucleotide sequence modified by a first labeling group as shown in SEQ ID NO:2; in the probe lefRPA-Probe-1, (n)a is a single-stranded DNA molecule with a nucleotide sequence as shown in SEQ ID NO:3, and (n)b is a single-stranded DNA molecule with a nucleotide sequence as shown in SEQ ID NO:4; The primer YP01-3F is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:5, and the primer YP01-3R-1 is a single-stranded DNA with a nucleotide sequence modified with a first labeling group as shown in SEQ ID NO:6; in the probe YP01-3Prboe-1, (n)a is a single-stranded DNA molecule with a nucleotide sequence as shown in SEQ ID NO:7, and (n)b is a single-stranded DNA molecule with a nucleotide sequence as shown in SEQ ID NO:8; The primer bscp31RPA-F is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:9, the primer bscp31RPA-R-1 is a single-stranded DNA with a nucleotide sequence modified by a first labeling group as shown in SEQ ID NO:10, and in the probe bscp31RPA-Probe-1, (n)a is a single-stranded DNA molecule with a nucleotide sequence as shown in SEQ ID NO:11, and (n)b is a single-stranded DNA molecule with a nucleotide sequence as shown in SEQ ID NO:
12.
2. The kit according to claim 1, characterized in that The first labeling group is biotin.
3. The kit according to claim 1, characterized in that The second labeling group is independently selected from one of FITC, TAMRA, FAM, HEX, CY3, CY5, ROX, Texas Red, and digoxigenin.
4. The kit according to claim 1, characterized in that The blocking groups are independently selected from one of C3 spacer, C6 spacer and C9 spacer.
5. A kit for detecting anthrax bacillus, pestis bacillus and brucella, characterized in that: Including a composition for detecting anthrax bacillus, a composition for detecting pestis bacillus and a composition for detecting brucella; The composition for detecting Bacillus anthracis comprises a primer lefRPA-F, a primer lefRPA-R and a probe lefRPA-Probe; The composition for detecting Yersinia pestis includes primer YP01-3F, primer YP01-3R and probe YP01-3Prboe; the composition for detecting Brucella includes primer bscp31RPA-F, primer bscp31RPA-R and probe bscp31RPA-Probe; The general structural formula of the probe lefRPA-Probe, the probe YP01-3Prboe, and the probe bscp31RPA-Probe is shown in Formula 2: 5'-(n)cH-(n)dY-3' Formula 2; In Formula 2, (n)c is a first single-stranded DNA molecule modified with a fluorescent group, H is a tetrahydrofuran residue, (n)d is a second single-stranded DNA molecule modified with a quenching group, and Y is a blocking group; The primer lefRPA-F is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO: 1, the primer lefRPA-R is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO: 2, and in the probe lefRPA-Probe, (n)c is a single-stranded DNA molecule with a nucleotide sequence modified with a fluorescent group as shown in SEQ ID NO: 3, and (n)d is a single-stranded DNA molecule with a nucleotide sequence modified with a quenching group as shown in SEQ ID NO: 4; The primer YP01-3F is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:5, the primer YP01-3R is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:6, and in the probe YP01-3Prboe, (n)c is a single-stranded DNA molecule with a nucleotide sequence modified with a fluorescent group as shown in SEQ ID NO:7, and (n)d is a single-stranded DNA molecule with a nucleotide sequence modified with a quenching group as shown in SEQ ID NO:8; The primer bscp31RPA-F is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:9, the primer bscp31RPA-R is a single-stranded DNA with a nucleotide sequence as shown in SEQ ID NO:10, and in the probe bscp31RPA-Probe, (n)c is a single-stranded DNA molecule with a nucleotide sequence modified with a fluorescent group as shown in SEQ ID NO:11, and (n)d is a single-stranded DNA molecule with a nucleotide sequence modified with a quenching group as shown in SEQ ID NO:
12.
6. A composition, characterized in that The composition comprises at least one of the composition for detecting anthrax bacillus, the composition for detecting pestis bacillus and the composition for detecting brucella in the kit according to any one of claims 1 to 4.
7. A composition, characterized in that The composition comprises at least one of the composition for detecting anthrax Bacillus, the composition for detecting pestis Bacillus and the composition for detecting Brucella in the kit according to claim 5.
8. Use of the kit according to any one of claims 1 to 4 and / or the kit according to claim 5 and / or the composition according to claim 6 and / or the composition according to claim 7 in any of the following aspects: A1) Detection or auxiliary detection of pathogens; A2) Preparation of products for pathogen detection or auxiliary detection; The pathogenic bacteria is at least one of anthrax bacillus, pestis bacillus and brucella.
9. A method for detecting pathogenic bacteria, characterized in that: include: B1) Extract genomic DNA of the sample to be tested; B2) using the genomic DNA as a template, performing LFD-RPA detection using the composition of claim 6 or the kit of any one of claims 1 to 4; determining whether the sample to be tested contains the pathogen according to the bands in the lateral flow test paper; The pathogenic bacteria is at least one of anthrax bacillus, pestis bacillus and brucella.
10. A method for detecting pathogenic bacteria, characterized in that: include: C1) Extract genomic DNA of the sample to be tested; C2) using the genomic DNA as a template, performing RPA detection using the composition of claim 7 or the kit of claim 5; determining whether the sample to be tested contains the pathogen according to the intensity of the fluorescent signal; The pathogenic bacteria is at least one of anthrax bacillus, pestis bacillus and brucella.
Citation Information
Cited By
Primer combination and kit for simultaneously detecting three hematogenous parasites
CN120738377A
